<DOC>
	<DOCNO>NCT01579916</DOCNO>
	<brief_summary>This prospective annual release study design ass safety trivalent influenza virus vaccine use two new strain recommend 2012-2013 influenza season previously contain trivalent intranasal FluMist vaccine . Three hundred healthy adult receive single dose vaccine placebo follow 180 day study vaccination .</brief_summary>
	<brief_title>A Study Evaluate Safety 3 New 6:2 Influenza Virus Reassortants Adults</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled release study enroll approximately 300 healthy adult 18 49 year age . Eligible subject randomly assign 4:1 fashion receive single dose trivalent vaccine placebo intranasal spray . Randomization stratify site . This study conduct 3 site United States America . Each subject receive one dose investigational product Study Day 1 . The duration study participation subject time study vaccination 180 day study vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age 18 49 year time investigational product administration 2 . Written inform consent locally require authorization ( ie , HIPAA USA ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation 3 . Females childbearing potential sexually active nonsterilized male partner must use effective contraception 30 day prior study vaccination , must agree continue use precaution 60 day study vaccination 4 . Nonsterilized male sexually active female partner childbearing potential must use effective method contraception prior study vaccination amd must agree continue use precaution least 30 day receipt study vaccination 5 . Healthy medical history physical examination 6 . Female subject childbearing potential must also negative urine blood pregnancy test screening , screen Day 1 occur day , day vaccination prior randomization . 7 . Subject available telephone 8 . Ability understand comply requirement protocol , judge investigator 9 . Ability complete followup period 180 day dose require protocol 1 . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result 2 . Concurrent enrollment another clinical study 180 day receipt investigational product ( Day 181 ) 3 . Employees clinical study site individual involve conduct study , immediate family member individual 4 . History hypersensitivity component vaccine , include egg egg protein serious , life threatening , severe reaction previous influenza vaccination 5 . History hypersensitivity gentamicin 6 . Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( eg , asthma ) , chronic metabolic disease ( eg , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year 7 . Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( eg , cough sore throat ) within 14 day prior randomization 8 . Any known immunosuppressive condition immune deficiency disease , include human immunodeficiency virus infection , ongoing immunosuppressive therapy 9 . History GuillainBarré syndrome 10 . A household contact severely immunocompromised ( eg , hematopoietic stem cell transplant recipient , period immunocompromised individual require care protective environment ) ; additionally , subject avoid close contact severely immunocompromised individual least 21 day study vaccination 11 . Receipt investigational agent within 30 day prior randomization , expect receipt 30 day study vaccination ( use license agent indication list package insert permit ) 12 . Receipt nonstudy vaccine within 30 day prior randomization , expect receipt 30 day study vaccination 13 . Expected receipt antipyretic analgesic medication daily every day basis randomization 14 day study vaccination 14 . Administration intranasal medication within 14 day prior randomization , expect receipt 14 day study vaccination 15 . Receipt influenza antiviral therapy antiviral agent within 48 hour prior study vaccination expect receipt influenza antiviral therapy antiviral agent 14 day study vaccination 16 . Known suspected mitochondrial encephalomyopathy 17 . Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Trivalent , Influenza , FluMist , Vaccine , Prevention</keyword>
</DOC>